RedHill Biopharma Advances Development of RHB-102
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
RedHill Biopharma announced development progress for RHB-102 in multiple GI indications, including its development, via the accelerated FDA 505(b)(2) route, as a once-daily oral ondansetron therapy for GLP-1/GIP receptor agonist therapy-associated GI side effects, such as nausea, vomiting and diarrhea, that are estimated to significantly limit growth in the multi-billion-dollar GLP-1 market. RedHill further announced that it is currently pursuing potential U.S. FDA approval of RHB-102 for oncology support, with additional potential for use in post-operative nausea and vomiting. If approved by FDA, RHB-102 could be the first oral 24-hour extended-release ondansetron antiemetic drug for the treatment of CINV/RINV. Expansion of RHB-102's intellectual property coverage for relevant indications, including GLP-1-associated nausea and vomiting, has also advanced.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like RDHL with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on RDHL
About RDHL
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RedHill Biopharma's RHB-102 Progress Drives 36% Rally, Stock Drops 4.29%
- Stock Volatility: RedHill Biopharma's stock fell 4.29% to $1.34 on Tuesday after a 36% rally on Monday, indicating potential profit-taking that may affect investor confidence in the short term.
- Development Progress: The company announced advancements for RHB-102 (Bekinda) in multiple gastrointestinal indications, utilizing the FDA's accelerated 505(b)(2) pathway, which aims to address GI side effects associated with GLP-1/GIP receptor agonist therapies, presenting significant market potential.
- Clinical Data Support: Clinical data for RHB-102 comes from the U.S. Phase 3 GUARD gastroenteritis study and the positive Phase 2 IBS-D study, both meeting their primary endpoints, which are expected to provide strong support for FDA approval and potentially reshape the GLP-1 market landscape.
- Market Impact: With up to 50% of patients discontinuing GLP-1 receptor agonists within three months due to side effects, successful development of RedHill's therapy could mitigate the projected $35 billion reduction in GLP-1 market valuations by 2030.
Continue Reading
Cyclerion Therapeutics Expands Collaboration with Medsteer, Shares Surge 44.2%
- Significant Stock Surge: Cyclerion Therapeutics shares rose 44.2% to $1.99 in pre-market trading, reflecting strong market confidence in the company's expanded strategic collaboration with Medsteer, indicating positive investor sentiment towards future growth prospects.
- Deepening Strategic Collaboration: The partnership with Medsteer aims to advance the closed-loop anesthetic platform CYC-126, which is expected to accelerate the product's market entry, thereby enhancing the company's competitive edge in the anesthesia sector.
- Optimistic Market Outlook: With continuous advancements in anesthetic technology, Cyclerion's new platform is poised to meet the increasing medical demand, further driving revenue growth and strengthening its position in the healthcare industry.
- Increased Investor Confidence: The substantial stock price increase not only reflects market approval of the company's strategic direction but may also attract more investor interest, thereby supporting future financing and expansion efforts.
Continue Reading